Ellen Bradley
Assistant Professor of Psychiatry at the University of California, San Francisco
Data updated
Research Footprint
Ellen Bradley appears in 6 tracked papers (2021–2025), most studied alongside Psilocybin, across Depressive Disorders, Safety & Risk Management and Anxiety Disorders.
Most-cited paper: Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice (49 citations).
Frequent co-authors: Joshua Woolley, Jordan Aday and Balázs Szigeti.
Background & Research
Ellen Bradley, MD is a psychiatrist and faculty member at UCSF’s Department of Psychiatry and Behavioral Sciences. Her research and clinical work focus on psychedelic-assisted therapy, including psilocybin studies for mood disorders and Parkinson’s disease, as well as the psychotherapy components of psychedelic treatment. UCSF lists her as an Assistant Professor, and her profile notes training at Stanford, Yale, and UCSF.
Key Impact
She is a UCSF psychiatrist and psychedelic clinical researcher involved in psilocybin studies for depression, bipolar depression, Parkinson’s disease, and psychotherapy methods.
Collaboration Network
5 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Ellen Bradley is associated with.
University of California, San Francisco
academicUniversity of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →